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Abstract: This case-controlled clinical trial was performed on the salivary 8-hydroxyguanosine (8-OHdG)
levels in smokers and non-smokers with chronic periodontitis after non-surgical periodontal therapy.
Subjects (N = 40) with periodontitis (smokers and non-smokers) and with clinically healthy conditions
(smokers and non-smokers) were assigned to this study. At baseline, clinical periodontal parameters
(plaque index, gingival index, pocket probing depth and clinical attachment levels) were evaluated. Saliva
samples were obtained pre- and post-treatment to quantify the 8-OHdG levels using Elisa technique.
Subjects diagnosed with chronic periodontitis with smoking habit (CPs) and non-smokers (CPns) received
scaling and root planing. In clinically healthy subjects with smoking habit (CHs) and non-smokers
(CHns), only oral hygiene tutoring was performed. All clinical measurements and salivary collection
were repeated in a 3-month recall interval. Data were analyzed using Anova, Tukey post hoc test and
Mann-Whitney ’U’ tests (P < 0.05). At baseline, CPs and CPns groups showed significantly higher PI,
GI, PD and CAL values than those of CHns and CHs (P < 0.001). Baseline salivary levels of 8-OHdG
were significantly higher in CPs group (14.775 pg/mL) (P < 0.001) compared to the other groups. All
clinical parameters in chronic periodontitis group improved at the 3rd month recall interval, however,
with regards to 8-OHdG values, the CP smoker category still had a higher level compared to CP non-
smoker. This study reflects an on-going periodontal destructive status in smokers and salivary 8-OHdG
levels could be recognized as an oxidative biomarker for determining periodontal tissue destruction.
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Abstract: The purpose of this case controlled clinical trial is to study the salivary 8-
Hydroxyguanosine (8-OHdG) levels in smokers and non-smokers with chronic periodontitis after 
non-surgical periodontal therapy. Subjects (N=40) with periodontitis (smokers and non-smokers) 
and with clinically healthy conditions (smokers and non-smokers) were assigned to this study. At 
baseline, clinical periodontal parameters (plaque index, gingival index, pocket probing depth and 
clinical attachment levels) were evaluated. Saliva samples were obtained pre and post treatment in 
order to quantify the 8-Hydroxyguanosine (8-OHdG) levels. Subjects diagnosed with chronic 
periodontitis with smoking habit (CPs) and non-smokers (CPns) received scaling and root planing 
(SRP). In clinically healthy subjects with smoking habit (CHs) and non-smokers (CHns), only 
scaling and oral hygiene tutoring were performed. All clinical measurements and salivary collection 
were repeated in a 3 month recall interval. 8-OHdG levels were measured using a competitive 
enzyme immunoassay technique. Data were analyzed using Anova, Tukey post hoc test and Mann 
Whitney ‘U’ tests (alpha=0.05). At baseline, CPs and CPns groups showed significantly higher PI, 
GI, PD and CAL values than those of CHns and CHs (P<0.001). Baseline salivary levels of 8-
OHdG were significantly higher in CPs group (14.775 pg/mL) (P<0.001) compared to the other 
groups. All clinical parameters in chronic periodontitis group improved at the 3rd month recall 
interval, however with regards to  8-OHdG values, the CP smoker category still had a  higher level 
compared to  CP non smoker .Hence, reflecting an on-going periodontal destructive status. The 
results of this study exhibits salivary 8-OHdG levels could be recognized as an oxidative biomarker 
for determining periodontal tissue destruction. 
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Periodontitis is an inflammatory disorder wherein complex interactions between the 
microorganisms, host response mechanisms and environmental factors result in tissue damage. 
Among the environmental factors, smoking has been linked with increased morbidity and mortality. 
Over the last decade, there have been a number of reviews that have considered the biological 
mechanisms underlying susceptibility of smokers to periodontitis in [1,2]. As per demographic 
records, smokers demonstrate a 2.6 to 6 fold increased incidence of periodontitis compared to 
non-smokers [3] and decreased response to periodontal therapy [4,5].  
Despite the fact that a clear dose-response relationship between chronic periodontitis and smoking 
was reported [6], the mechanisms by which smoking contributes to the pathogenesis of 
periodontitis are not yet clearly understood. However, smokers are more likely to harbour a higher 
prevalence of potential periodontal pathogens, which could influence host-cytokine levels [7,8]. 
   The past few decades have gathered strong evidence which implicates oxidative stress in the 
pathogenesis of periodontal disease [9,10]. Free radicals and reactive oxygen species (ROS) at 
normal levels are essential for normal biological processes [11] that could also have deleterious 
effects at higher concentrations leading to oxidative damage. Generally, the homeostatic balance 
between ROS and free radicals are disturbed by various factors one which is smoking that may 
enhance oxidative stress not only through the production of reactive oxygen radicals in smoke but 
also through weakening of the antioxidant defence systems [12,13]. ROS and in particular the 
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active hydroxyl (OH) group radical, are known to be involved in the destruction of various 
functional macromolecules, like free and conjugated proteins, lipids and carbohydrates eventually 
resulting in cellular damage [14,15]. Polymorphonuclear leukocytes (PMN) are the initial defence 
cells that predominantly encircles the area accumulated by bacterial pathogens in pathological 
conditions including periodontitis . Such an infiltration in numbers is likely to lead to an increase in 
ROS levels [16]. 
   8-Hydroxyguanosine (8-OHdG) is an oxidized nucleoside that is excreted in the body fluids as a 
reparative consequence of DNA. A stable product that is formed as a result of enzymatic 
dissolution after ROS induces 8-hydroxylation of guanine base on mitochondrial and nuclear DNA 
[17,18]. Studies have demonstrated that the 8-OHdG released in body fluids and tissues has been 
implicated in the pathogenesis of malignancy, inflammatory, autoimmune disorders and diabetes 
mellitus [19,20].  
   A correlation between the salivary levels of 8-OHdG and periodontal microbiota has been 
reported indicating its effectiveness as a supportive biomarker for determination of periodontal 
status [21,22]. Furthermore, a recent clinical investigation has revealed that initial periodontal 
therapy has a beneficial effect on decreasing the substantial levels of oxidative biomarkers in 
smokers and non-smokers [23], thus validating its use as a signature molecule in diagnosis. 
However, the association between smoking and its effect on diseased periodontium at a cellular 
level still remains uncertain.  
The primary objectives of this study therefore were to estimate the salivary levels of 8-OHdG in 
smokers and non-smokers with chronic periodontitis and also to determine its level after initial 




Materials and methods 
Study groups  
The present case controlled clinical trial with an intervention arm, involved a total of 40 subjects 
(n=10 per group), comprising of  group 1 = smokers with chronic periodontitis (CPs), group 2=non-
smokers with chronic periodontitis (CPns), group 3= clinically healthy smokers (CHs) and group 4= 
non-smokers with clinically healthy periodontium (CHns). Ethical approval was obtained from the 
institutional review board. All  participants were informed regarding the study and a written 
informed consent was obtained on voluntary participation. Subjects were excluded if they had any 
systemic disease/immune-compromised condition, or recent history of intake of antibiotics, anti-
inflammatory and anti-oxidants and dietary supplements. 
Diagnosis for chronic periodontitis was based on the 1999 international world workshop for 
classification of periodontal diseases and conditions [24]. A clinical and radiographic assessment 
characterized recruitment of chronic periodontitis patients by at least 30% teeth with pockets >5 
mm. Smokers were categorized based on verbal query of ≥10 cigarettes/day for more than 5 
years. Non-smoker groups were subjects who fulfilled the norms of not having smoked cigarettes 
in their lifetime. The healthy group of individuals were categorized based on systemic well-being, 
having teeth with pocket depth ≤3 mm, no attachment loss, no bleeding on gentle probing and with 
radiographic confirmation of no bone loss. 
 
Clinical measurements and initial periodontal therapy 
Only subjects who fulfilled the inclusion criteria were incorporated into the clinical trial. All clinical 
measurements were performed by a single examiner. Initially, 5 ml of unstimulated whole saliva 
samples were obtained in Eppendorf tubes [25] prior to clinical examination in order to avoid any 
contamination of the oral fluids which could deter the results. Then, basic periodontal parameters 
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comprising of Plaque index (PI) [26], Gingival Index (GI) [27], Probing pocket depth (PPD) and 
Clinical attachment level (CAL) were recorded on a standard form. PD and CAL were assessed on 
six sites of a tooth where the deepest probing depth was recorded using William’s periodontal 
probe. Subsequently, all patients received scaling and root planing (SRP), which were completed 
in at least 2 appointments. As per the routine norm, oral hygiene instructions were given to all 
subjects. In clinically healthy smoker and non-smoker category, only scaling and oral hygiene 
tutoring were performed. All clinical measurements and salivary collection were repeated in the 3 
month recall interval. The collected saliva samples were centrifuged (2.000 g for 10 min) and the 
supernatants were stored at -80˚C until they were assayed.  
 
Detection of 8OHdG 
In order to detect the levels of 8-OHdG in saliva, a competitive enzyme immunoassay, Elisa kit 
(Cloud-Clone Corp, Houston, Texas, USA) was used according to the manufacturer’s instructions. 
The detection range was  74.07 – 6000 pg/mL. 
 
Statistical analysis 
The data collected was entered into microsoft excel spreadsheet and analyzed using IBM SPSS 
Statistics, Version 22(Armonk, NY: IBM Corp). Descriptive data were presented in the form of 
mean, median, standard deviation and quartiles. Based on the distribution of the data, parametric 
or non parametric tests were used. Comparison of the study variables at baseline was done using 
ANOVA with Tukey post hoc test. Post treatment statistical data was analyzed by Independent 
sample t test. Paired t test was used compare the study variables between baseline and post 
treatment.  Mann Whitney ‘U’ test was used to compare the change in the clinical parameters and 
8 OHdG levels for chronic periodontitis (CP and CP smokers) post periodontal therapy. Pearson’s 
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and  Spearman’s correlation test was used to test the correlation between the study variables and 
8-OHdG. P value less than 0.05 were considered to be statistically significant in all tests. 
   
Results 
All patients involved in this clinical trial returned for the follow-up visits. With regards to gender 
distribution, only males had volunteered to participate. The age of subjects with chronic 
periodontitis (smokers and non-smokers) were 40-65 years while the age of the healthy controls 
were between 25 and 35 years.  
Baseline clinical findings  
At baseline, chronic periodontitis (smoker and non-smoker) group presented significantly higher 
values of PI, GI, PD and CAL compared to clinically healthy (smoker and non-smoker) group 
(P<0.001) (Table 1a). The salivary levels of 8-OHdG exhibited significantly higher levels in CP 
smokers group (14.775 pg/mL) (P<0.001) compared to the other test groups (Table 1a). 
Comparison of clinical variables between the groups at baseline revealed, notable statistical 
significance in all groups, except in PI values in the clinically healthy smokers and non smokers 
and the PPD and CAL values between the chronic periodontitis  and clinically healthy smokers and 
non-smokers (Table 1b). 
  
Post treatment (3-month) recall period. 
Initial periodontal therapy was provided only for CP (smoker and non-smoker) group. The other 
two groups belonged to the healthy category and hence only oral health measures were instructed. 
All clinical parameters demonstrated reduction in measurements at the 3rd month recall interval 
(Table 2). Considering comparisons between groups 1 & 2, the PI ranges did display reduction but 
were not statistically significant among the groups .However, the CP non-smoker category display 
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marked significant reduction in GI values compared to CP smoker category (P < 0.001). Likewise, 
the post treatment 8 OHdG levels were seen to reduce in both groups, with predisposition in the 
CP non smoker group (P<0.001) (Table 2).  
 
Baseline-post periodontal therapy comparison 
Intergroup comparison within CP groups  demonstrated significant reduction in all parameters , 
except in PPD levels in CP non-smokers category (Table 3). Notable changes were examined in 
the variables during the study period between the CP groups using the Mann Whitney U test, 
which showed all significant figures except in variables of CAL and 8OHdG, wherein no statistical 
changes were observed (Table 4). 
 
Correlation between 8OHdG levels and clinical variables 
A positive correlation was observed post treatment between 8OHdG and PPD levels in Group 2 
(r= 0.63), which exhibited a statistical significant effect (p=0.04) (Table 5) 
 
Discussion 
The present clinical trial has been conducted to relate the relevance of oxidative damage induced 
by ROS that are liberated during periodontal disease process and the damage caused by the 
influence of smoking on the periodontium. For this purpose, 8-OHdG was chosen as a biomarker 
for estimation of oxidative DNA damage. The deleterious effects of oxidative stress generally 
follows after exposure to a high concentration of ROS and/or inadequate functioning of antioxidant 
defence system within the host. Lately, this has been linked to various systemic diseases including 
periodontitis [9,23]. 
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In this study, at baseline clinical parameters (PI, GI, PD and CAL) of the chronic periodontitis 
group (smokers and non-smokers) showed higher values compared to the healthy category 
(smokers and non-smokers) which validates the periodontal disease process. Saliva is a naturally 
available biofluid that can be collected with ease from the patient without any need of sophisticated 
tool. It contains various constituents which reflects the relationship between periodontal disease 
and diseases of other systemic tissues/organs. Literature review have revealed that unstimulated 
saliva contains some GCF elements and tissue metabolites which are beneficial for estimation of 
periodontal disease [28,29]. In advanced periodontal disease with hopeless prognosis, salivary 
8OHdG levels were found to be high, suggesting its role as a biomarker [22,30,31]. In this present 
study, the levels of 8-OHdG in saliva were significantly higher in the chronic periodontitis and 
smoker groups  compared to clinically healthy category. Similar results were observed previously 
where higher levels of this oxidative biomarker were correlated to the clinical parameters [31]. The 
findings in this study also supported its useful role as an oxidative indicator. In comparison, in the 
smokers category (chronic periodontitis smokers and clinically healthy smokers) higher mean 
values of 8-OHdG were observed. This could be explained by the fact that cigarette smoke 
contains large quantities of ROS [32] and 8-OHdG, being the main by-product of hydroxyl radical 
attack on DNA that could be regarded as a dependable biomarker for oxidative damage since it 
can be ascertained with high sensitivity [33].  
Long term exposure to cigarette smoke was reported to increase ROS levels, which in turn 
decrease the antioxidant status and hindered the DNA restorative capacity that finally led to 
oxidative DNA damage. Hence, this mechanism led to determining 8-OHdG levels in monitoring 
oxidative damage in smokers [34].  
Salivary flow rate is another factor, found to increase with periodontitis [35], which could be causal 
for the higher levels of 8 –OHdG levels in CP subjects. However, literature related to long term 
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effects of smoking shows hypofunction of the salivary glands and hence  decreased quantity and 
quality of salivary flow rate [36,37]. However, our findings indicated higher levels of 8-OHDG levels 
in chronic periodontitis and smokers category, reflecting the 8-OHDG as a convincible biomarker 
of inflammatory destruction. Additionally, age criteria is also a factor that needs to be considered 
while quantifying this biomarker. A study conducted  by Gan W et al [38] observed an age-
dependant rise in the levels of 8-OHdG marker levels over a wide age group. Since the age group 
of CP patients in the current study, belonged to 40-65 years, it could have influenced the higher 
range of the biomarker. However, the high range of 8OHdG marker in the healthy smoker category 
( age range 25-35 years) is perhaps the reflection of inflammatory destruction. 
After initial periodontal therapy, all clinical parameters and salivary 8-OHdG levels decreased, 
which was in accordance with a previous study where significant decrease in 8-OHdG levels both 
in saliva and GCF were observed [23]. However, work carried out by Dede et al [39] did not 
comply with the present results, as the authors did not observe a decrease in salivary levels. Also, 
the present study showed a reduction in biomarker levels in CP non-smokers group after treatment 
compared to the CP smoker category at the 3rd month recall. This could be attributed to the 
combined effect of periodontal destruction enhanced by smoking in the CP smokers group. 
Literature has provided evidence that smokers tend to respond less favourable to periodontal 
therapy [4,40,41].  
Considering the GI values, CP non-smokers demonstrated considerable reduction after SRP 
compared to CP smokers category. This was supported by the study conducted by Ah et al [4], in 
which the GI scores in non-smokers were decreased after initial therapy compared to smoker 
group. This was explained by the decrease in wound healing process in smokers. 
Considering the comparison of clinical variables from baseline to 3rd month recall visits, 
demonstrated significant reduction in  both CP groups, except for  the PPD levels in CP non-
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smoker group. This state cannot be mitigated with conventional periodontal therapy alone and may 
require further surgical intervention for pocket elimination.  
With regards to changes in the variables during the study interval, almost all parameters 
demonstrated significant reduction, except for the clinical attachment levels. This was in 
agreement with  previous studies [42,43] wherein the authors have suggested the possibility of a 
local effect of cigarette and the high serum cotinine levels to be among the reasons for clinical 
attachment loss. Likewise, post therapeutic difference in           8-OHdG biomarker levels between 
the two CP groups were also not statistically significant, reflecting that further invasive treatment 
may be required for complete healing of tissues. 
   The 3rd month recall interval was chosen according to the plaque control protocol described by 
Axelsson and Lindhe [44], which was found to be effective against recurrence of periodontitis. The 
clinically healthy smokers who were acquainted with the smoking habit for at least 5 year period, 
did not have any periodontal disease. In this study, PI scores in periodontally healthy smokers 
were comparatively less than the CP groups, which justifies that, well maintained oral health and 
host response are responsible for disease predisposition. 
In the present study, voluntary participation of both genders were intended to be recruited but no 
female participants  joined the trial . This could probably be due to the social stigma of revealing 
the smoking status. The community where the study was conducted, does not completely accept 
habitual smoking in woman. Hence, only males were observed to be under the participant 








The results of the current study suggest that salivary 8-OHdG values can be utilized as an 
oxidative biomarker for determining periodontal tissue destruction. However, it may not serve as a 
beneficial determinant to quantify the periodontal destruction occurring in chronic periodontitis 
smokers and non-smokers category. 
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Captions to legends:   
Table 1a:- Comparison of the variables between the study groups at baseline 
Table 1b:- Pairwise comparison of the variables between the study groups at baseline 
Table 2:- Comparison of the variables between the study groups at post treatment 
Table 3:- Comparison of the variables between baseline and post treatment  in chronic 
periodontitis groups 
Table 4:-Comparison of change in the variables during study period between chronic periodontitis 
groups 























1	 10	 2.17	 0.18	
343.59	 <0.001*	
2	 10	 1.88	 0.25	
3	 10	 0.33	 0.05	
4	 10	 0.34	 0.12	
Baseline	GI	
1	 10	 1.59	 0.11	
1408.92	 <0.001*	
2	 10	 1.80	 0.06	
3	 10	 0.12	 0.05	
4	 10	 0.22	 0.05	
Baseline	PPD	
1	 10	 6.40	 1.35	
62.96	 <0.001*	
2	 10	 5.90	 0.88	
3	 10	 2.10	 0.57	
4	 10	 1.90	 0.88	
Baseline	CAL	
1	 10	 7.00	 1.56	
82.65	 <0.001*	
2	 10	 7.50	 2.46	
3	 10	 0	 0	




1	 10	 14.78	 2.39	
155.73	 <0.001*	
2	 10	 5.11	 1.10	
3	 10	 7.06	 1.25	
4	 10	 1.09	 0.08	





























2 0.29 0.08 0.002* 0.09 0.49 
3 1.84 0.08 <0.001* 1.64 2.04 
4 1.83 0.08 <0.001* 1.63 2.04 
2 
3 1.55 0.08 <0.001* 1.35 1.75 
4 1.54 0.08 <0.001* 1.34 1.74 
3 4 -0.01 0.08 0.99(NS) -0.21 0.19 
Baseline GI 
1 
2 -0.21 0.03 <0.001* -0.30 -0.12 
3 1.47 0.03 <0.001* 1.38 1.55 
4 1.37 0.03 <0.001* 1.28 1.46 
2 
3 1.68 0.03 <0.001* 1.59 1.77 
4 1.58 0.03 <0.001* 1.49 1.67 
3 4 -0.10 0.03 0.03* -0.19 -0.01 
Baseline PPD 
1 
2 0.50 0.43 0.65(NS) -0.65 1.65 
3 4.30 0.43 <0.001* 3.15 5.45 
4 4.50 0.43 <0.001* 3.35 5.65 
2 
3 3.80 0.43 <0.001* 2.65 4.95 
4 4.00 0.43 <0.001* 2.85 5.15 
3 4 0.20 0.43 0.97(NS) -0.95 1.35 
Baseline CAL 
1 
2 -0.50 0.65 0.87(NS) -2.26 1.26 
3 7.00 0.65 <0.001* 5.24 8.76 
4 7.00 0.65 <0.001* 5.24 8.76 
2 
3 7.50 0.65 <0.001* 5.74 9.26 
4 7.50 0.65 <0.001* 5.74 9.26 
3 4 0.00 0.65 1.00(NS) -1.76 1.76 
Baseline  8OHdG 
levels (pg/mL) 
1 
2 9.66 0.65 <0.001* 7.91 11.41 
3 7.71 0.65 <0.001* 5.96 9.46 
4 13.69 0.65 <0.001* 11.93 15.44 
 19 
2 
3 -1.95 0.65 0.02* -3.70 -0.20 
4 4.02 0.65 <0.001* 2.27 5.78 
3 4 5.97 0.65 <0.001* 4.22 7.73 
Tukey Post Hoc Test 




















1	 10	 0.72	 0.12	
0.05	 -0.05	 0.15	 1.00	 18	 0.33(NS)	
2	 10	 0.67	 0.10	
Post	GI	
1	 10	 0.69	 0.10	
0.35	 0.27	 0.43	 9.46	 18	 <0.001*	
2	 10	 0.33	 0.06	
Post	
PPD	
1	 10	 5.30	 1.70	
-0.30	 -1.60	 1.00	 -0.49	 18	 0.63(NS)	
2	 10	 5.60	 0.97	
Post	
CAL	
1	 10	 5.50	 2.42	
-0.60	 -2.98	 1.78	 -0.53	 18	 0.60(NS)	





1	 10	 13.33	 2.32	
9.12	 7.48	 10.76	 11.68	 18	 <0.001*	
2	 10	 4.22	 0.84	
Independent sample t test 





















Baseline 10 2.17 0.18 
1.45 1.32 1.58 25.41 9 <0.001* 
Post 10 0.72 0.12 
GI 
Baseline 10 1.59 0.11 
0.90 0.78 1.02 16.74 9 <0.001* 
Post 10 0.69 0.10 
PPD 
Baseline 10 6.40 1.35 
1.10 0.47 1.73 3.97 9 0.003* 
Post 10 5.30 1.70 
CAL 
Baseline 10 7.00 1.56 
1.50 0.53 2.47 3.50 9 0.007* 
Post 10 5.50 2.42 
8OHdG 
levels(pg/ml) 
Baseline 10 14.78 2.39 
1.44 0.68 2.21 4.27 9 0.002* 
Post 10 13.33 2.32 
2 
PI 
Baseline 10 1.88 0.25 
1.21 1.03 1.39 15.50 9 <0.001* 
Post 10 0.67 0.10 
GI 
Baseline 10 1.80 0.06 
1.47 1.43 1.50 91.12 9 <0.001* 
Post 10 0.33 0.06 
PPD 
Baseline 10 5.90 0.88 
0.30 -0.38 0.98 1.00 9 0.34(NS) 
Post 10 5.60 0.97 
CAL 
Baseline 10 7.50 2.46 
1.40 0.90 1.90 6.33 9 <0.001* 




Baseline 10 5.11 1.10 
0.90 0.48 1.31 4.92 9 0.001* 
Post 10 4.22 0.84 
Paired t test 










Table 4  
 
 Groups N Mean(SD) Range 
Median(Q1-
Q3) 





1 10 1.45 (0.18) 
1.20- 
1.70 
1.44 (1.27 - 1.62) 
18.5 0.02* 
2 10 1.21 (0.25) 
0.72- 
1.74 
1.21 (1.14 - 1.26) 
GI 
1 10 0.90 (0.17) 
0.70- 
1.22 
0.87 (0.77 - 1.07) 
0 <0.001* 
2 10 1.47 (0.05) 
1.42- 
1.60 
1.45 (1.44 - 1.48) 
PPD 
1 10 1.10 (0.88) 
0.00- 
3.00 
1.00 (0.75 - 1.25) 
18.5 0.008* 
2 10 0.30 (0.95) 
0.00- 
3.00 
0.00 (0.00 - 0.00) 
CAL 
1 10 1.50 (1.35) 
0.00- 
4.00 
1.00 (0.75 - 3.00) 
46.5 0.77(NS) 
2 10 1.40 (0.70) 
1.00- 
3.00 
1.00 (1.00 - 2.00) 
8OHdG levels 
(pg/ml) 
1 10 1.44 (1.07) 
0.15- 
3.67 
1.24 (0.52 - 2.04) 
36 0.29(NS) 
2 10 0.90 (0.58) 
0.13- 
2.11 
0.87 (0.40 - 1.29) 
*p<0.05 statistically Significant,    p>0.05 Non Significant, NS 


















Groups   
8OHdG levels (pg/ml) 
Baseline# Post# Change## 
1 
P1 
Correlation Coefficient -0.11 -0.45 0.16 
p-value 0.77(NS) 0.19(NS) 0.65(NS) 
GI 
Correlation Coefficient 0.21 -0.07 0.07 
p-value 0.56(NS) 0.85(NS) 0.84(NS) 
PPD 
Correlation Coefficient 0.19 0.13 0.54 
p-value 0.59(NS) 0.72(NS) 0.11(NS) 
CAL 
Correlation Coefficient -0.45 -0.27 0.04 
p-value 0.20(NS) 0.45(NS) 0.92(NS) 
2 
P1 
Correlation Coefficient -0.22 0.12 0.00 
p-value 0.55(NS) 0.75(NS) 1.00(NS) 
GI 
Correlation Coefficient -0.31 -0.06 0.06 
p-value 0.39(NS) 0.87(NS) 0.86(NS) 
PPD 
Correlation Coefficient 0.21 0.63 -0.17 
p-value 0.57(NS) 0.04* 0.63(NS) 
CAL 
Correlation Coefficient -0.001 -0.07 0.05 
p-value 1.00(NS) 0.84(NS) 0.90(NS) 
# Pearson’s correlation test 
## Spearmans correlation test 
*p<0.05 statistically significant,   p>0.05 Non significant, NS 
